scispace - formally typeset
J

Jurgen Herre

Researcher at Cambridge University Hospitals NHS Foundation Trust

Publications -  43
Citations -  2941

Jurgen Herre is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Computer science & Innate immune system. The author has an hindex of 12, co-authored 29 publications receiving 2638 citations. Previous affiliations of Jurgen Herre include University of Cambridge & University of Oxford.

Papers
More filters
Journal ArticleDOI

Dectin-1 Mediates the Biological Effects of β-Glucans

TL;DR: It is shown that Dectin-1 mediates the production of TNF-α in response to zymosan and live fungal pathogens, an activity that occurs at the cell surface and requires the cytoplasmic tail and immunoreceptor tyrosine activation motif of Dect in addition to Toll-like receptor (TLR)-2 and Myd88.
Journal ArticleDOI

Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages

TL;DR: Dectin-1, a proinflammatory nonopsonic receptor for beta-glucans, is examined, and it is shown that it mediates the internalization of beta- glucan-bearing ligands, including yeast particles.
Journal ArticleDOI

Dectin-1 and its role in the recognition of β-glucans by macrophages

TL;DR: It is shown that Dectin-1, a murine type II C-type lectin-like receptor, was able to non-opsonically recognize β- 1,3 and β-2,6 linked glucan rich particles and intact yeast.
Journal ArticleDOI

The role of SIGNR1 and the beta-glucan receptor (dectin-1) in the nonopsonic recognition of yeast by specific macrophages.

TL;DR: This study has studied the mannose-binding potential of murine Mφ and identified the dendritic cell-specific ICAM-3-grabbing nonintegrin homolog, SIGN-related 1 (SIGNR1), as a major MR on murine resident peritoneal M φ.
Journal ArticleDOI

Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion

TL;DR: Among patients without substantial lung entrapment, the outpatient administration of talc through an indwelling pleural catheter for the treatment of malignant pleural effusion resulted in a significantly higher chance of pleurodesis at 35 days than an ind welling catheter alone, with no deleterious effects.